Dana-Farber Cancer Institute and OncoHost partner for renal cell carcinoma research
Accounting for 4% of all cases, kidney cancer is currently the sixth most common cancer diagnosed in the UK
Read More
Tag: renal cell carcinoma
Opdivo plus Cabometyx approved in the EU for advanced renal cancer
Opdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer’s Sutent in a Phase III trial
Read More
Priority review for Merck & Co’s belzutifan in rare kidney cancer subset
Belzutifan is a potential treatment for von Hippel-Lindau disease-associated renal cell carcinoma
Read More
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
NICE says the combination’s cost-effectiveness estimate is higher than what is considered acceptable for NHS use
Read More
NICE appraisal for BMS kidney cancer immunotherapy combination
The Institute gave a positive FAD to the Opdivo and Yervoy combination in renal cell carcinoma, approving funding via the Cancer Drugs Fund.
Read More
EMA validates Bavencio for review in advanced RCC
European regulators have validated Merck’s application Bavencio for review in kidney cancer.
Read More
Keytruda combination found to reduce risk of death in RCC
MSD’s Keytruda in combination with Pfizer’s Inlyta has been found to reduce the risk of death by nearly half in patients with advanced renal cell carcinoma (RCC).
Read More
NICE turns down Opdivo/Yervoy combo for kidney cancer
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma.
Read More
Merck, Pfizer intend to file Bavencio, Inlyta combo
Merck KGaA and Pfizer say they intend to seek US approval of a combination of Bavencio and Inlyta for kidney cancer on the back of progression-free survival data from a late-stage trial.
Read More
FDA widens scope of Pfizer’s Sutent in kidney cancer
The US Food and Drug Administration has cleared Pfizer’s Sutent for adjuvant treatment of adults at a high risk of their kidney cancer returning after a kidney has been removed.
Read More
EUSA bags EU approval for kidney cancer drug
The European Commission has licensed EUSA Pharma’s Fotivda for the management of adult patients with advanced kidney cancer across the European Union as well as Norway and Iceland.
Read More
NICE turns down kidney cancer drugs
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
